Fieldpoint Private Securities’s Viking Therapeutics VKTX Stock Holding History

Fieldpoint Private Securities’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,426	Closed	-$15K	–	1742
2021 Q3	$15K	Hold	2,426	–	–	﹤0.01%	922
2021 Q2	$14K	Sell	2,426 -31	-1%	-$184	﹤0.01%	928
2021 Q1	$16K	Sell	2,457 -729	-23%	-$5.13K	﹤0.01%	860
2020 Q4	$18K	Buy	+3,186	New	+$19.3K	﹤0.01%	723
2020 Q1	–	Sell	-9,688	Closed	-$78K	–	551
2019 Q4	$78K	Buy	9,688 +6,001	+163%	+$43.7K	0.02%	361
2019 Q3	$25K	Sell	3,687 -302	-8%	-$2.24K	0.01%	490
2019 Q2	$33K	Buy	+3,989	New	+$34.1K	0.01%	473

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fieldpoint Private Securities's VKTX Position: Q4 2021 in Review

Fieldpoint Private Securities sold out of Viking Therapeutics (VKTX) in Q4 2021, closing a stake of 2,426 shares — an estimated $15K sold.

Fieldpoint Private Securities first reported a position in VKTX in Q2 2019 and held it in 7 quarters. The position peaked at $78K in Q4 2019. 140 funds tracked by Wall St. Rank hold VKTX as of Q4 2021.

Fieldpoint Private Securities reported no remaining Viking Therapeutics position as of Q4 2021 after selling out during the quarter.
Fieldpoint Private Securities sold 2,426 Viking Therapeutics shares in Q4 2021, an estimated $15K.
Fieldpoint Private Securities first reported a position in Viking Therapeutics in Q2 2019 and held it in 7 quarters.
Fieldpoint Private Securities's Viking Therapeutics position peaked at $78K in Q4 2019.
140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2021.

Based on Fieldpoint Private Securities's 13F filing for Q4 2021, filed 24 Jan 2022.